Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)

Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/33935

Title:	Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)
Authors:	Buti, Maria Stepanova, Tatjana Celen, Mustafa K. Flisiak, Robert Ryder, Stephen D. Streinu, Adrian Cercel Flaherty, John F. Gaggar, Anu Suri, Vithika Mo, Shuyuan Subramanian, Mani Nurmukhametova, Elena Zoulim, Fabien Andreone, Pietro Marcellin, Patrick Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı/Gastroenteroloji Bilim Dalı. Gürel, Selim HLH-8209-2023
Keywords:	Gastroenterology & hepatology
Issue Date:	Oct-2017
Publisher:	Wiley
Citation:	Buti, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.
Description:	Bu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.
URI:	https://aasldpubs.onlinelibrary.wiley.com/loi/15273350 http://hdl.handle.net/11452/33935
ISSN:	0270-9139 1527-3350
Appears in Collections:	Scopus Web of Science

Files in This Item:

There are no files associated with this item.

DSpace JSPUI